Integral Diagnostics Trades At Half What Private Buyers Pay

Fund managers detail a deep valuation gap to private market radiology deals as an activist holder pushes for change

13 Jul 2026 · 6 min read

Investors Mutual Limited laid out a simple valuation gap in a July 2026 interview on Integral Diagnostics: private market radiology transactions like Qscan Imaging have transacted at around 12 times EBITDA, while Integral, the country's second-largest radiology player with a strong footprint across Queensland, Victoria and Western Australia, trades on less than 8 times EBITDA, roughly a 50 per cent discount. The manager said a new management team's more consistent approach to operating margins should improve on a history of volatility, and that at current valuations it would not be surprising to see a competitive takeover bid emerge, given the company's market leadership, demographic tailwinds and a fully franked dividend yield above 4 per cent.

If this valuation continues at these sorts of levels, it wouldn't surprise me to see a competitive bid for that business because it is trading cheap, it is a market leader, and it's got long term tailwinds behind it.

— Investors Mutual Limited, Interview, July 2026

An activist buyer pushing for change

Wilson Asset Management took a more hands-on approach to the same gap in May 2026, describing itself as having gone substantial in the company specifically to instigate change. The manager said the business trades at roughly 7 times enterprise value to EBITDA while comparable private transactions, including the Healius radiology business, transacted at double that multiple, and argued the board should pursue debt reduction, potential divestment of parts of the business better suited to competitors, and ultimately a share buyback once the balance sheet is repaired. The manager also welcomed an incoming new CEO as a positive step for the business.

The frustrating part about this business is trades I think are seven times enterprise value to EBITDA multiple. I think private transactions and the Healius radiology business transacted for double that. So something's not right in the market, but there is value there, there's no question.

— Wilson Asset Management, Article, May 2026

Structural tailwinds building since the Capitol Health merger

Underneath the valuation debate sits a genuine set of structural growth drivers. LSN Capital Partners described Integral in early 2026 as a transition stock benefiting from MRI deregulation, the GP bulk billing incentive and the national lung cancer screening program, with merger synergies from the Capitol Health acquisition upgraded to $14 million from $10 million at the time of the original deal. The manager noted Integral holds around 14 per cent market share as the number three player in a structurally growing industry, forecasting earnings growth above 20 per cent annually over the next three years. Lennox Capital Partners, an early and growing holder, pointed to a decade of 5 to 35 per cent annual revenue growth underpinned by an ageing population, low scans-per-capita penetration by global standards, and an ongoing shift in mix toward higher-priced MRI scans.

Not every manager is convinced

Seneca Financial Solutions offered a more sceptical read in October 2025, describing diagnostic imaging as a surprisingly mediocre sector overall, generating around 5 per cent growth and 5 per cent return on equity, and flagging labour force inflation and the risk of top practitioners splintering off into boutique competitors as ongoing challenges, even while acknowledging the regulatory tailwinds others cite. Oracle Advisory Group exited its position entirely in December 2025, arguing companies with high staff costs and government-set pricing come under particular pressure in an inflationary environment. Forager Funds rated the stock a hold in May 2026, saying the situation around GP referrals and margins remained too messy for the fund to get comfortably involved despite recognising Integral's healthy market share following the Capitol Health acquisition.

What managers are watching next

With a new CEO now in place and the board under pressure from activist holders like Wilson Asset Management to address the balance sheet, the key questions for managers are whether Integral can deliver the more consistent operating margins Investors Mutual Limited says the market is waiting for, whether the upgraded $14 million in Capitol Health merger synergies fully materialises, and whether the persistent gap to private market transaction multiples ultimately closes through a re-rating or an outright takeover approach.